3.74
前日終値:
$3.785
開ける:
$3.8
24時間の取引高:
2.49M
Relative Volume:
1.45
時価総額:
$285.35M
収益:
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.2621
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
-0.53%
1か月 パフォーマンス:
-3.11%
6か月 パフォーマンス:
-46.42%
1年 パフォーマンス:
-56.00%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
FULC
Fulcrum Therapeutics Inc
|
3.74 | 285.35M | 80.00M | -76.12M | -63.88M | -1.1465 |
|
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | JP Morgan | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, In - The National Law Review
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Kaplan Fox Reminds Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Ongoing Securities Law Investigation - The National Law Review
Fulcrum Therapeutics faces investigation after stock halves due to halted sickle cell drug program. - Pluang
Fulcrum Therapeutics (FULC) Holds Steady at $3.77 as Traders Eye Range BoundariesBullish Pattern Stocks - siam.in
Fulcrum Therapeutics (FULC) Edges Higher to $3.79 as Shares Test Upper RangeMomentum Trade - siam.in
Kaplan Fox Urges Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Invest - The National Law Review
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Live Fulcrum Therapeutics, Inc. (FULC) Technical Analysis - Traders Union
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inv - The National Law Review
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ... - pmg-ky3.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to an Ongoing Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inves - The National Law Review
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse - kalkine.ca
Kaplan Fox Launches Investigation Into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - The National Law Review
Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - Kalkine Media
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse - kalkine.ca
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan
Fulcrum (NASDAQ: FULC) plans special cash dividend ahead of Slate Medicines merger - Stock Titan
Fulcrum Therapeutics faces securities probe aft... - Pluang
Fulcrum Therapeutics Inc. (FULC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - The Globe and Mail
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Programme Discontinuation Triggers 51% Stock Drop - kalkine.ca
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance
Fulcrum (FULC) Close: Ends Up by 0.26% at $3.84; Chart View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionVolatility Smile - vinanet.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Fulcrum (FULC) Stock: Falls 0.52% to $3.83 at the Close; Chart View: Support at $3.64 and Resistance at $4.02 Frame the Range in the Latest SessionAnalyst Upgrade Stocks - vinanet.vn
Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEnergy Earnings Report - dars.gov.et
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire
Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Slate Medicines to Merge With Fulcrum Therapeutics - Cooley
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger - Legal Desire
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement with Key Financial Details - Kalkine Media
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com
What's Going On With Fulcrum Therapeutics Stock Monday?Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field - AllSci
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):